Microvillus Inclusion Disease (MVID) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Microvillus Inclusion Disease (MVID) Market Outlook
Thelansis’s “Microvillus Inclusion
Disease (MVID) Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2024 To 2034" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Microvillus Inclusion Disease
(MVID) treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
Microvillus
Inclusion Disease (MVID) Overview
Microvillus
Inclusion Disease (MVID) is a rare, autosomal recessive congenital enteropathy
characterized by severe, intractable secretory diarrhea and profound
malabsorption, typically presenting within the first days of life. Affected
infants may experience rapid fluid loss—sometimes up to 30% of body weight
within 24 hours—leading to life-threatening dehydration and metabolic acidosis.
Diagnosis relies on clinical suspicion, exclusion of more common causes of
neonatal diarrhea, and confirmation via intestinal biopsy, which reveals villus
atrophy and characteristic microvillus inclusions within enterocytes, without
evidence of infection or inflammation. MVID is most commonly caused by
biallelic loss-of-function mutations in the MYO5B gene, which encodes myosin
Vb, a motor protein essential for apical membrane trafficking in intestinal
epithelial cells. In some cases, mutations in STX3, encoding syntaxin 3—a SNARE
protein involved in vesicle fusion—have been identified, typically associated
with later onset and a milder phenotype. While historically considered fatal,
advances in supportive care, including long-term parenter.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment